Access our latest E-book: Empowering genomics with high-throughput proteomics

When planning multiplex immunoassay experiments, a thorough study planning process is imperative for generating reproducible data and gaining translatable biological insights for wider applications. Here are 5 key steps to consider before running a multiplex immunoassay: 1. Clearly define research question – to provide focus and direction across all stages of study execution, including the experimental design, sample collection and handling, data collection and processing, as well as the limitations of the study. 2. Select suitable controls – to ensure a valid comparative analysis and meaningful results, the experimental and control groups should be matched as closely as possible to reduce confounding factors, such as age, ethnicity, sex, and underlying conditions. 3. Power your study – to ensure a higher probability of correctly detecting a difference between the study groups, given that the effect is there. Calculating power for a study is based on assumptions on the effect size – the magnitude of difference between the study groups. If there is no overlap between the data in the experimental group and the control group, there is a considerable difference, and the effect size and thus the study power are high, thereby requiring a smaller sample size. However, if the overlap is larger than the difference between the groups, the effect size is less significant, resulting in lower power, and a need for a larger sample size. 4. Apply consistency in protein sample collection and storage – to minimize pre-analytical factor influence on the data output and confidence with which conclusions are drawn. A set of factors related to sample collection, processing, and storage should be considered when measuring proteins in biological samples and interpreting results. While efforts to minimize the effects introduced by pre-analytical variability should aim to be consistent. Documenting the sample collection, handling, and storage process is therefore imperative for obtaining meaningful results, even with samples that have not been handled optimally. 5. Randomize samples appropriately to study type – to minimize the possibility of missing true biological variation or misidentifying it as e.g. technical variations. While the overall goal is to minimize the experimental variables across the study, different considerations will apply to different study types, such as single- or multi- plate studies, multi-batch studies or studies with longitudinal design. Ideally, a power analysis should be performed before collecting samples and running a study. However, power calculations can also be performed retrospectively, or when adding additional samples to the study is not an option. In this case, the calculation can tell us if we will have enough power to justify the study. Alternatively, retrospective calculations may be useful when designing a scaled-up study from a smaller pilot. Are you interested in learning more about how to successfully plan your multiplex immunoassay experiment? Download our eBook “Setting New Quality Standards for Multiplex Immunoassays” and read more about key considerations and essential tips for planning your experiment, including how to perform power analysis, how to minimize pre-analytical variation, as well as how to randomize your samples based on your study type. Furthermore, learn how with Olink’s free set of tools and resources on Olink Insight can help you streamline your study planning and execution!

The identification and analysis of protein biomarker signatures play a critical role in precision medicine. Recent years have marked a significant leap forward in this domain, thanks to significant technological advancements in multiplex protein analysis. This blog post explores these developments, highlighting key technologies that have transformed our approach to protein measurements including bead-based immunoassay and electrochemiluminescence (ECL), their critical role in cytokine profiling, biomarker panels, and the challenges that persist in optimizing specificity and sensitivity. Multiplex Immunoassay vs. ELISA: What’s the Difference? Before we explore the advancements, let’s clarify a common question: How does a multiplex immunoassay differ from the traditional ELISA (Enzyme-Linked Immunosorbent Assay)? ELISA is a widely used immunoassay method for detecting and quantifying substances such as proteins, using a single target per assay. Its specificity and sensitivity have made it a benchmark in immunoassay platforms for clinical diagnostics. However, ELISA is limited by its ability to analyze only one biomarker per sample, which can be time-consuming and sample-intensive for comprehensive biomarker profiling. Multiplex Immunoassay, on the other hand, enables measurement of multiple targets simultaneously within a single sample. Techniques like bead-based immunoassay and electrochemiluminescence (ECL) were useful for the efficient study of complex biomarker signatures and cytokine profiling. This method conserves sample volume and significantly reduces the time and cost associated with biomarker analysis. Key Technologies in Multiplex Immunoassays Bead-Based Immunoassay: This technique utilizes color-coded microspheres (beads) linked to distinct fluorophores, enabling the quantification of hundreds of distinct proteins. It is pivotal for protocols for multiplex immunoassay, especially in cytokine profiling and biomarker panel analysis. Electrochemiluminescence (ECL): ECL-based multiplex immunoassays employ an array of analyte-specific capture antibodies on a solid matrix. These assays are chosen for high specificity and sensitivity. Microfluidics Cartridge-Based Assays: Leveraging microfluidic devices, these assays separate and detect multiple proteins in a single sample. Innovations in immunoassay multiplexing 1980 – 1990’s Flourescent-based Light-absorbing reactions to quantify protein concentrations. Small degree of multiplexing can be achieved by using distinct colors of flourescence for different proteins. 1990’s Chemiluminescent-based Light-producing reactions to quantify protein concentrations. Some degree of multiplexing can be achieved by using distinct chemiluminescent tags or physical separation of reaction. 2000’s Bead-based Color-coded microspheres to allow for quantification of hundreds of distinct proteins in a single sample. Electrochemiluminescence-based Electric current to stimulate a light-producing reaction that is proportional to the protein concentration. Multiplexing of up to ten proteins can be achieved by using patterned arrays where each spot on the array is coated with a different capture antibody. 2010’s Microfluidics cartridge-based Microfluidic devices to separate and detect multiple proteins in a single sample. Degree of multiplexing is lower than bead-based assays. Proximity Extension Assay (PEA) Pairs of antibodies labeled with DNA oligonucleotides, which upon target binding and hybridization form a new DNA molecule by proximity extension. The resulting DNA barcode is then quantified using qPCR or NGS, allowing for highly multiplexed and sensitive protein measurements. The Imperative for a Higher Degree of Multiplexing The highlighted multiplex technologies have been instrumental in allowing simultaneous measurement of multiple target analytes. However, it needs to be acknowledged that there is a growing demand for technologies capable of achieving even greater levels of multiplexing. Such advancements are essential for comprehensive biomarker signatures, understanding disease mechanisms and propelling the field of precision medicine. However, as we push the boundaries of multiplexing, the performance of these assays — in terms of specificity, sensitivity, and accuracy — becomes increasingly critical. Inaccuracies or lack of assay specificity and sensitivity can lead to misinterpretations of data, impacting research findings. What is the solution to multiplexing with optimal performance? Among the various technologies available, the Proximity Extension Assay (PEA) combines antibody- and DNA-based methodologies to provide a unique immunoassay that delivers unwavering performance regardless of the number of analytes that are being multiplexed. A critical differentiator of PEA as a tool for biomarker discovery and validation is the ability to quality control all steps of the reaction in each individual sample, and the ability to extract data from only 1 μL of sample. For researchers interested in clinical diagnostics and therapeutic development facilitated by multiplexing technologies or interested in benchmarking immunoassay platforms, downloading our detailed ebook will provide you with a wealth of information. This includes challenges and opportunities in multiplexing, study planning and experimental design, data analysis and interpretation and case studies to uncover biomarker signatures with potential clinical utility.

Multiplex immunoassay technologies enable the simultaneous detection of multiple target analytes in the same sample and assay workflow. These powerful methods support cytokine profiling or the development of protein biomarker panels for the advancement of precision medicine. Furthermore, one can expect multiplexing increases analytical efficiency, cost-effectiveness, and reduces sample volume requirements. The transition from the traditional analysis of single biomarkers to more comprehensive biomarker signatures brings a more holistic approach to disease understanding and improves the discrimination power of statistical models. How to ensure data quality when multiplexing? Leveraging the full potential of multiplex immunoassays in biomarker research is not completely straightforward. Researchers may encounter challenges with cross-reactivity, signal interference, low sensitivity, high variability, limited dynamic range and other issues that affect the assay’s performance and reliability. Addressing these challenges is crucial for harnessing the capabilities of multiplex immunoassays in biomarker panel development and cytokine profiling. Key strategies include the careful selection of highly specific capture and detection antibodies to reduce cross-reactivity, and the optimization of assay conditions to minimize signal interference and variability. Leverage the full potential of Multiplex Immunoassays in Biomarker Research This Ebook offers a detailed exploration of the main challenges in multiplexing immunoassays and how to bypass them by using the Proximity Extension Assay (PEA) – a technology that sets a new quality standard by effectively addressing the challenges commonly encountered. PEA technology has the revolutionary capability to measure multiple target analytes in just 1 μL of sample. The Ebook also addresses practical tips on study design, data analysis, and interpretation. Table of contents: Chapter 1: Multiplexing: Challenges and Opportunities Chapter 2: Study Planning and Experimental Design Chapter 3: Data Analysis and Interpretation Chapter 4: Case Studies: Robust Biomarker Signatures with Potential Clinical Utility Main challenges in multiplex immunoassays Cross-Reactivity Cross-reactivity represents a significant hurdle, where capture and detection antibodies may bind to non-target antigens, leading to false-positive results. Minimizing cross-reactivity is essential for ensuring the assay’s specificity and accuracy. Signal Interference Signal interference, arising from the assay’s components, readout measures or the sample itself, can obscure the detection of target analytes, compromising the assay’s sensitivity and overall performance. Low Sensitivity The challenge of low sensitivity is particularly acute when detecting low-abundance biomarkers, making it difficult to identify crucial, yet scarce, analytes in complex samples. High Variability High variability in assay results undermines the reproducibility and reliability of multiplex immunoassays. Limited Dynamic Range The analytes combined in a single assay can span a wide range of concentrations. This variability in concentration of each analyte, coupled with differing dilution requirements, narrows the overall dynamic range available for the assay. Consequently, this limitation complicates the simultaneous analysis of samples with highly variable biomarker levels. Lack of Appropriate Quality Controls The inherent complexity of multiplex assays calls for robust quality controls to validate and ensure the reliability of results. Complex Data Analysis The vast amount of information generated from a single multiplex immunoassay requires sophisticated statistical methods to accurately interpret the findings. Laborious Validation Extensive validation is necessary to confirm the specificity, sensitivity, and reproducibility of multiplex immunoassays, demanding significant time and resources.

Explore more insights, tips, and research breakthroughs in proteomics and immunoassay technology. Stay ahead with expert commentary and the latest advancements shaping the future of biomedical science.